Drugs / Burfiralimab
Burfiralimab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04817202 | Sep 2020 → Jan 2022 | — | ImmuneMed, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03653208 | Nov 2018 → Feb 2020 | — | ImmuneMed, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06306339 | Mar 2024 → May 2025 | rheumatoid arthritis | ImmuneMed, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05808335 | Jan 2022 → Mar 2024 | chronic hepatitis B virus infection | ImmuneMed, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04679350 | Mar 2021 → Nov 2022 | COVID-19 | ImmuneMed, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04679415 | Dec 2020 → Aug 2021 | COVID-19 | ImmuneMed, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04676971 | Dec 2020 → Aug 2021 | COVID-19 | ImmuneMed, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Burfiralimab | “A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)” NCT05808335 ↗ |
| Known as | humanized Virus Suppressing Factor-variant 13 | “after single intravenous (IV) administration of hzVSF-v13 (humanized Virus Suppressing Factor-variant 13) in healthy male volunteers” NCT03653208 ↗ |
| Known as | hzVSF-v13 | “A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)” NCT05808335 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody (mAb)” NCT04676971 ↗ |
| Route | Intravenous | “100 mg hzVSF-v13 IV + SOC” NCT04676971 ↗ |